Loading clinical trials...
Loading clinical trials...
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alexion Pharmaceuticals, Inc.
NCT06903234 · Hemoglobinuria, Paroxysmal
NCT00566696 · Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), and more
NCT00997386 · Hematologic Neoplasms, Multiple Myeloma, and more
NCT00438789 · Hemoglobinuria, Paroxysmal
NCT01760096 · Paroxysmal Nocturnal Hemoglobinuria, Hemoglobinuria, and more
Norris Comprehensive Cancer Center
Los Angeles, California
Stanford University Medical Center, Division of Hematology
Stanford, California
Hartford Hospital, Cancer Clinical Research Office
Hartford, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions